

07 Aug 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast version of Five Must-Know Things: planned US drug pricing legislation in focus; solid quarter but no Seagen announcement for Merck & Co; AbbVie's Gonzalez sounds alarm over US pricing legislation; Alnylam ready to expand in amyloidosis; and Boehringer Ingelheim on global Jardiance strategy.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 5 August 2022, including: planned US drug pricing legislation in focus; solid quarter but no [Seagen Inc.](#) announcement for [Merck & Co., Inc.](#); [AbbVie Inc.](#)'s Gonzalez sounds alarm over US pricing legislation; [Alnylam Pharmaceuticals Inc.](#) ready to expand in amyloidosis; and [Boehringer Ingelheim GmbH](#) on global Jardiance strategy.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Pharma Braces For Potential Landmark Moment For US Drug Price Controls](#)" - Scrip, 2 Aug, 2022.)

(Also see "[Merck's Solid Quarter Doesn't Soothe Seagen M&A Watchers](#)" - Scrip, 28 Jul, 2022.)

(Also see "[AbbVie's Gonzalez Sounds Alarm On US Drug Price Negotiation Proposal](#)" - Scrip, 29 Jul, 2022.)

(Also see "[*Alnylam Ready To Expand TTR Franchise With Positive Cardiomyopathy Results*](#)" - Scrip, 3 Aug, 2022.)

(Also see "[*Boehringer Will Go 'Wide, Broad, Fast, Strong' If Jardiance Hits CKD Bullseye*](#)" - Scrip, 2 Aug, 2022.)

[Click here to explore this interactive content online](#) ✎